Evidence map›Paper›PMID 35672772›Full record

ArticleMalaria journal2022

Comparison of two malaria multiplex immunoassays that enable quantification of malaria antigens.

Ihn Kyung Jang, Alfons Jiménez, Andrew Rashid, Rebecca Barney, Allison Golden, Xavier C Ding, Gonzalo J Domingo, Alfredo Mayor

Open access · goldAbstract read
In one paragraph

Article in Malaria journal, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.0field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 6 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 4 countries.

Ihn Kyung JangDiagnostic Group, PATH, 2201 Westlake Ave, Suite 200, Seattle, WA, 98121, USA. ikjang@path.org.ORCID http://orcid.org/0000-0001-8899-7930
Alfons JiménezISGlobal, Barcelona Institute for Global Health, Hospital Clínic-Universitat de Barcelona, Carrer Rosselló 153 (CEK Building), 08036, Barcelona, Spain.
Andrew RashidDiagnostic Group, PATH, 2201 Westlake Ave, Suite 200, Seattle, WA, 98121, USA.
Rebecca BarneyDiagnostic Group, PATH, 2201 Westlake Ave, Suite 200, Seattle, WA, 98121, USA.
Allison GoldenDiagnostic Group, PATH, 2201 Westlake Ave, Suite 200, Seattle, WA, 98121, USA.
Xavier C DingThe Foundation for Innovative New Diagnostics, Campus Biotech, 9 Chemin des Mines, 1202, Geneva, Switzerland.
Gonzalo J Domingo *Diagnostic Group, PATH, 2201 Westlake Ave, Suite 200, Seattle, WA, 98121, USA.
Alfredo Mayor *ISGlobal, Barcelona Institute for Global Health, Hospital Clínic-Universitat de Barcelona, Carrer Rosselló 153 (CEK Building), 08036, Barcelona, Spain.
Program for Appropriate Technology in Health · USBarcelona Institute for Global Health · ESEduardo Mondlane University · MZFIND · CH

Funding

Bill and Melinda Gates Foundation INV1135840Spanish Ministry of Science and Innovation CEX2018-000806-S
6 · The paper itself

Abstract

backgroundImmunoassay platforms that simultaneously detect malaria antigens including histidine-rich protein 2 (HRP2)/HRP3 and Plasmodium lactate dehydrogenase (pLDH), are useful epidemiological tools for rapid diagnostic test evaluation. This study presents the comparative evaluation of two multiplex platforms in identifying Plasmodium falciparum with presence or absence of HRP2/HRP3 expression as being indicative of hrp2/hrp3 deletions and other Plasmodium species. Moreover, correlation between the malaria antigen measurements performed at these platforms is assessed after calibrating with either assay standards or international standards and the cross-reactivity among Plasmodium species is examined.

methodsA 77-member panel of specimens composed of the World Health Organization (WHO) international Plasmodium antigen standards, cultured parasites for P. falciparum and Plasmodium knowlesi, and clinical specimens with mono-infections for P. falciparum, Plasmodium vivax, and Plasmodium malariae was generated as both whole blood and dried blood spot (DBS) specimens. Assays for HRP2, P. falciparum-specific pLDH (PfLDH), P. vivax-specific pLDH (PvLDH), and all human Plasmodium species Pan malaria pLDH (PanLDH) on the Human Malaria Array Q-Plex and the xMAP platforms were evaluated with these panels.

resultsThe xMAP showed a higher percent positive agreement for identification of hrp2-deleted P. falciparum and Plasmodium species in whole blood and DBS than the Q-Plex. For whole blood samples, there was a highly positive correlation between the two platforms for PfLDH (Pearson r = 0.9926) and PvLDH (r = 0. 9792), moderate positive correlation for HRP2 (r = 0.7432), and poor correlation for PanLDH (r = 0.6139). In Pearson correlation analysis between the two platforms on the DBS, the same assays were r = 0.9828, r = 0.7679, r = 0.6432, and r = 0.8957, respectively. The xMAP HRP2 assay appeared to cross-react with HRP3, while the Q-Plex did not. The Q-Plex PfLDH assay cross-reacted with P. malariae, while the xMAP did not. For both platforms, P. knowlesi was detected on the PvLDH assay. The WHO international standards allowed normalization across both platforms on their HRP2, PfLDH, and PvLDH assays in whole blood and DBS.

conclusionsQ-Plex and xMAP show good agreement for identification of P. falciparum mutants with hrp2/hrp3 deletions, and other Plasmodium species. Quantitative results from both platforms, normalized into international units for HRP2, PfLDH, and PvLDH, showed good agreement and should allow comparison and analysis of results generated by either platform.

Indexed as

MalariaMalaria, FalciparumMalaria, VivaxPlasmodium knowlesiAntigens, ProtozoanDiagnostic Tests, RoutineHumansImmunoassayL-Lactate DehydrogenasePlasmodium falciparumProtozoan ProteinsSensitivity and SpecificityAntigens, ProtozoanL-Lactate DehydrogenaseProtozoan ProteinsHRP2hrp2/hrp3 deletionsImmunoassayMalariaMultiplexP. falciparumP. knowlesipLDHP. malariaeP. vivaxStandardization

Identifiers

PMID35672772
PMCPMC9171962
OpenAlexW4281648189

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.